Ā | Patients number (%) |
---|---|
Gender | |
āMale | 106 (63.5) |
āFemale | 61 (36.5) |
Cancer familiarity | |
āYes | 101 (60.5) |
āNo | 43 (25.7) |
āUnknown | 23 (13.8) |
Comorbidity | |
āYes | 52 (31.1) |
āNo | 115 (68.9) |
Performance Status sec. ECOG | |
ā0 | 99 (59.3) |
ā1 | 36 (21.6) |
ā2ā3 | 12 (7.1) |
āUnknown | 20 (12.0) |
Histology | |
āAdenocarcinoma | 147 (88.0) |
āSquamous | 7 (4.2) |
āOther/Mixed | 13 (7.8) |
T descriptor according to TNM | |
ā1ā2 | 102 (61.1) |
ā3ā4 | 65 (39.9) |
N descriptor according to TNM | |
ā0 | 36 (21.6) |
ā1 | 19 (11.4) |
ā2 | 66 (39.5) |
ā3 | 46 (27.5) |
M descriptor according to TNM | |
ā0 | 66 (39.5) |
ā1 | 101 (60.5) |
Disease stage | |
āI-II | 36 (21.6) |
āIII-IV | 131 (78.4) |
Grading | |
ā1 | 12 (7.2) |
ā2 | 15 (9.0) |
ā3 | 42 (25.1) |
āUnknown | 98 (58.7) |
Smoking status | |
āCurrent | 56 (33.5) |
āFormer | 68 (40.7) |
āNever | 34 (20.4) |
āUnknown | 9 (5.4) |
Starting treatment | |
āSurgery | 47 (28.1) |
āNeoadjuvant | 3 (1.8) |
āChemo-radiotherapy | 17 (10.2) |
āChemotherapy | 75 (44.9) |
āSupport therapy | 25 (15.0) |
Response rate to 1st line therapy | |
āCR | 3 (1.8) |
āPR | 31 (18.6) |
āSD | 20 (12.0) |
āPD | 35 (21.0) |
āNP | 78 (46.6) |
ALK-CNG | |
ādisomic | 71 (42.5) |
ā3ā7 copies | 42 (25.1) |
ā>7 copies | 15 (9.0) |
āNA | 39 (23.4) |